ARR 17477Alternative Names: ARL 17477
Latest Information Update: 22 Jan 2007
At a glance
- Originator Astra Arcus USA; AstraZeneca R&D Charnwood
- Class Anti-ischaemics; Neuroprotectants
- Mechanism of Action Nitric oxide synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Pain; Stroke